Orgovyx carries a list price of roughly $2,900 per month in the United States, which works out to more than $400 per pill at full retail. That price tag reflects a combination of patent exclusivity, a complex licensing deal between two pharmaceutical companies, and the drug’s positioning as a clinically superior alternative to older injectable treatments for advanced prostate cancer.
What Orgovyx Actually Costs
The sticker shock is real. At U.S. retail, a 30-day supply of Orgovyx runs close to $2,900. That number looks even more striking when you compare it internationally. In Canada, the same drug costs about $215 per month at full retail price. The gap isn’t because the pill is different. It’s because the U.S. lacks the government price controls that exist in most other countries.
For context, injectable hormone therapies for prostate cancer (like leuprolide or degarelix) can appear cheaper on paper, but the comparison isn’t straightforward. Those injections require clinic visits, nurse administration time, and sometimes facility fees. A Canadian study estimated the cost of each in-clinic drug administration at roughly $125 USD, and patients on injectables typically need those visits every one to six months. Orgovyx, taken as a daily pill at home, eliminates those recurring costs entirely. Still, even accounting for hidden administration fees, Orgovyx’s U.S. price is significantly higher than the total cost of most injectable alternatives.
Patent Protection Blocks Competition
Orgovyx (relugolix) was approved by the FDA in December 2020, and its manufacturer has applied for patent term extensions that could keep generic competitors off the market for years. The FDA determined that the drug’s regulatory review period spanned over 13 years from initial testing through approval, and the patent holder has requested nearly five additional years of patent life based on that timeline. Until those patents expire and generics enter the market, there is no price competition for the drug itself.
Orgovyx is also not among the medications selected for Medicare price negotiation under the Inflation Reduction Act. The first two rounds of drugs chosen for negotiated pricing in 2026 and 2027 include blockbusters like Eliquis, Ozempic, and Xtandi (another prostate cancer drug), but Orgovyx didn’t make either list. That means Medicare will continue paying the manufacturer’s set price for the foreseeable future.
A Billion-Dollar Licensing Deal Built Into the Price
Behind Orgovyx sits an unusually large financial arrangement. Myovant Sciences, the company that developed the drug, signed a collaboration and licensing deal with Pfizer in late 2020. Pfizer paid $650 million upfront and committed to up to $3.8 billion more in milestone payments tied to regulatory approvals and sales targets. The two companies split profits and certain expenses equally in their shared markets.
That kind of deal doesn’t just happen in the background. When a drugmaker owes billions in milestone payments as sales grow, there’s a powerful incentive to keep prices high. Every dollar of revenue counts toward triggering the next payment tier, and both companies need to recoup their investments. Myovant also agreed to cover Pfizer’s share of certain allowable expenses, up to $100 million in 2021 and $50 million in 2022, adding further financial pressure during the drug’s early years on the market.
Clinical Advantages Justify Premium Pricing
Pharmaceutical companies don’t set prices in a vacuum. They price based partly on what they can argue the drug is worth compared to existing options, and Orgovyx has genuine clinical advantages that strengthen that argument.
In the pivotal HERO trial, Orgovyx outperformed leuprolide (the most widely used injectable) on a metric that matters enormously to patients: how quickly testosterone recovers after treatment stops. Within 90 days of discontinuation, 54% of men on Orgovyx had recovered normal testosterone levels, compared to just 3.2% of men on leuprolide. The median recovery time was about 86 days for Orgovyx versus 112 days for leuprolide. And 39% of Orgovyx patients regained at least 80% of their pre-treatment testosterone, compared to only 2% on the injectable.
This matters because low testosterone causes fatigue, bone loss, weight gain, depression, and sexual dysfunction. Faster recovery means a shorter window of those side effects after treatment ends. The HERO trial also showed a lower rate of major cardiovascular events with Orgovyx, which is particularly relevant since prostate cancer patients tend to be older men who already carry heart disease risk. These advantages give the manufacturer leverage to argue the drug deserves a premium price, even if patients and insurers find that premium hard to swallow.
What You’ll Actually Pay With Insurance
Most patients don’t pay the full $2,900 retail price, but out-of-pocket costs can still be significant. On Medicare Part D plans, Orgovyx is typically placed on Tier 5, the specialty drug tier. That’s the most expensive category, and it usually comes with coinsurance (a percentage of the drug’s cost) rather than a flat copay. Plans also require prior authorization before they’ll cover it, meaning your doctor has to submit documentation proving the drug is medically necessary.
Your actual cost depends on where you are in your plan’s coverage cycle. During the initial coverage phase, you might pay 25% to 33% of the drug’s cost. Once you hit the coverage gap (sometimes called the donut hole), costs shift again. Under the Inflation Reduction Act’s $2,000 annual out-of-pocket cap for Medicare Part D, which took effect in 2025, total yearly spending is now limited, but reaching that cap with a specialty-tier drug can happen within the first month or two of treatment.
For patients without insurance, Myovant offers a patient assistance program that may provide Orgovyx at no cost to eligible uninsured individuals. The company also has broader financial support resources available by phone. Commercial insurance patients may qualify for copay assistance cards that reduce monthly costs, though these programs typically don’t apply to government insurance like Medicare or Medicaid.
The Bigger Picture on Specialty Drug Pricing
Orgovyx’s price follows a familiar pattern in U.S. pharmaceuticals. A drug enters the market as the only oral option in its class, targets a large patient population (prostate cancer is the most common non-skin cancer in men), and faces no generic competition. The manufacturer sets a price that reflects both the drug’s clinical value and the maximum the market will bear. Insurance companies negotiate rebates behind the scenes, but list prices stay high because they serve as the starting point for those negotiations.
The fact that the same drug costs roughly $215 per month in Canada illustrates how much of Orgovyx’s U.S. price is driven by the American pharmaceutical pricing system rather than by manufacturing costs or the drug’s inherent value. Until patent expiration opens the door to generic relugolix, or until Orgovyx is selected for Medicare price negotiation, the price is unlikely to drop substantially.